Catalysts / OCGN
Upcoming FDA decisions and readouts we track for Ocugen, each with the filing that announced it.
FreeBioList tracks 5 catalysts for Ocugen (OCGN, listed on Nasdaq): 4 upcoming and 1 decided. They cover 2 programmes: OCU410ST (Stargardt disease (modifier gene therapy); Stargardt disease) and OCU400 (Retinitis pigmentosa (modifier gene therapy); Retinitis pigmentosa).
First on the list: the Phase 3 readout for OCU400 (Retinitis pigmentosa (modifier gene therapy)), guided by the company to Q1 2027. The furthest-out event tracked is Mid 2027. By stage, the upcoming rows are 1 Phase 2/3 readout, 1 Phase 3 readout and 2 Regulatory submissions.
Decided and on record:
Each outcome links to the filing or notice that reported it in the table below.
All 5 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Ocugen OCGN · Nasdaq | OCU410ST | Stargardt disease (modifier gene therapy) | Q3 2026 company guidance |
Phase 2/3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Ocugen OCGN · Nasdaq | OCU400 | Retinitis pigmentosa (modifier gene therapy) | Q1 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Ocugen OCGN · Nasdaq | OCU410ST | Stargardt disease | Q2 2027 company guidance |
Phase 2/3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Ocugen OCGN · Nasdaq | OCU400 | Retinitis pigmentosa | Q2 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Ocugen OCGN · Nasdaq | OCU410ST | Stargardt disease | Mid 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList